Open AccessAntitumor Effect of Suberoylanilide Hydroxamic Acid and Topotecan in Renal Cancer Cells
Author(s) -
Akinori Sato,
Tomohiko Asano,
Akio Horiguchi,
Keiichi Ito,
Makoto Sumitomo,
Tomohiko Asano
Publication year - 2011
Publication title -
oncology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.267
H-Index - 57
eISSN - 1555-3906
pISSN - 0965-0407
DOI - 10.3727/096504011x12970940207841
Subject(s) - topotecan , pharmacology , vorinostat , cancer research , histone deacetylase , combination therapy , medicine , histone deacetylase inhibitor , cancer , cancer cell , camptothecin , chemotherapy , chemistry , histone , biochemistry , gene
The treatment modality for advanced renal cancer is limited. The development of novel systemic therapies has long been waited for. Suberoylanilide hydroxamic acid (SAHA) is one of the most potent histone deacetylase (HDAC) inhibitors, which are promising novel anticancer agents. SAHA has already been tested in phase II clinical trials; however, its effectiveness has been found to be limited. Recently, the combination of SAHA and topoisomerase I inhibitor, topotecan, was shown to be effective, but this treatment strategy has not been tested in renal cancer cells. In the present study, we found that the combination of SAHA and topotecan effectively inhibited the growth of renal cancer cells by suppressing the expression of cyclin-dependent kinase (CDK) 4 and cyclin D1, and promoting retinoblastoma protein (Rb) dephosphorylation. Furthermore, the combination therapy was found to inhibit both the function and expression of HDACs, which may be one of the main mechanisms of the combination therapy. To the best of our knowledge, this is the first report that has revealed the combined beneficial effect of SAHA and topotecan on renal cancer cells. Combining SAHA and topotecan is thus a promising approach to the treatment of renal cancer.